Official Journal of the European Union

C 305

Volume 61

English edition

Information and Notices

30 August 2018

Contents

II *Information*

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2018/C 305/01 Non-opposition to a notified concentration (Case M.8970 — Sumitomo/Parkwind/Northwester2) [1] ... 1

2018/C 305/02 Non-opposition to a notified concentration (Case M.8879 — JERA Trading/LNG Optimisation) [1] 1

IV *Notices*

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2018/C 305/03 Euro exchange rates 2

2018/C 305/04 Explanatory Notes to the Combined Nomenclature of the European Union 3

2018/C 305/05 Explanatory Notes to the Combined Nomenclature of the European Union 4

2018/C 305/06 New national side of euro coins intended for circulation 6

European Data Protection Supervisor

2018/C 305/07 Summary of the opinion on the proposal for a recast of the Public Sector Information (PSI) re-use Directive 7

EN

[1] Text with EEA relevance.

NOTICES FROM MEMBER STATES

2018/C 305/08 Commission information notice pursuant to Article 16 (4) of Regulation (EC) 1008/2008 of the European Parliament and of the Council on common rules for the operation of air services in the Community — Imposition of public service obligations in respect of scheduled air services [1] 10

2018/C 305/09 Commission information notice pursuant to Article 16(4) of Regulation (EC) No 1008/2008 of the European Parliament and of the Council on common rules for the operation of air services in the Community — Modification of public service obligations in respect of scheduled air services [1] 11

2018/C 305/10 Commission information notice pursuant to Article 17(5) of Regulation (EC) No 1008/2008 of the European Parliament and of the Council on common rules for the operation of air services in the Community — Invitation to tender in respect of the operation of scheduled air services in accordance with public service obligations [1] 12

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

2018/C 305/11 Dangerous substances — List of authorisation decisions taken by the EEA EFTA States in accordance with Article 64(8) of Regulation (EC) No 1907/2006 (REACH) in the second half of 2017 13

2018/C 305/12 Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2017 15

V *Announcements*

ADMINISTRATIVE PROCEDURES

European Personnel Selection Office (EPSO)

2018/C 305/13 Notice of open competition 34

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2018/C 305/14 Prior notification of a concentration (Case M.9072 — KKR/Altice/SFR Filiale) — Candidate case for simplified procedure [1] 35

[1] Text with EEA relevance.

II

(Information)

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Non-opposition to a notified concentration

(Case M.8970 — Sumitomo/Parkwind/Northwester2)

(Text with EEA relevance)

(2018/C 305/01)

On 30 July 2018, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M8970. EUR-Lex is the online access to European law.

([1]) OJ L 24, 29.1.2004, p. 1.

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Euro exchange rates [1]

29 August 2018

(2018/C 305/03)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,1660	CAD	Canadian dollar	1,5093
JPY	Japanese yen	129,73	HKD	Hong Kong dollar	9,1524
DKK	Danish krone	7,4571	NZD	New Zealand dollar	1,7413
GBP	Pound sterling	0,90500	SGD	Singapore dollar	1,5941
SEK	Swedish krona	10,6923	KRW	South Korean won	1 299,27
CHF	Swiss franc	1,1385	ZAR	South African rand	16,8176
ISK	Iceland króna	124,90	CNY	Chinese yuan renminbi	7,9626
NOK	Norwegian krone	9,7475	HRK	Croatian kuna	7,4370
BGN	Bulgarian lev	1,9558	IDR	Indonesian rupiah	17 087,73
CZK	Czech koruna	25,745	MYR	Malaysian ringgit	4,8076
HUF	Hungarian forint	324,63	PHP	Philippine peso	62,375
PLN	Polish zloty	4,2838	RUB	Russian rouble	79,4075
RON	Romanian leu	4,6417	THB	Thai baht	38,140
TRY	Turkish lira	7,5236	BRL	Brazilian real	4,8451
AUD	Australian dollar	1,5989	MXN	Mexican peso	22,3252
			INR	Indian rupee	82,3405

[1] *Source*: reference exchange rate published by the ECB.

Explanatory Notes to the Combined Nomenclature of the European Union

(2018/C 305/04)

Pursuant to Article 9(1)(a) of Council Regulation (EEC) No 2658/87 [1], the Explanatory Notes to the Combined Nomenclature of the European Union [2] are hereby amended as follows:

On page 379

9401 Seats (other than those of heading 9402), whether or not convertible into beds, and parts thereof

The following text shall be added after the existing text:

'For the purposes of this heading, any reference to bamboo applies only to vegetable materials of heading 1401. On the other hand, for the purposes of this heading, any reference to wood or wooden applies also to bamboo plates of heading 4412. (See also note 1(b) and note 6 to Chapter 44).'

9403 Other furniture and parts thereof

The following text shall be added after the existing paragraph:

'The Explanatory Note to heading 9401 regarding the references to "bamboo" and "wood or wooden", applies mutatis mutandis.'

---

[1] Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (OJ L 256, 7.9.1987, p. 1).

[2] OJ C 76, 4.3.2015, p. 1.

Explanatory Notes to the Combined Nomenclature of the European Union

(2018/C 305/05)

Pursuant to Article 9(1)(a) of Council Regulation (EEC) No 2658/87 [1], the Explanatory Notes to the Combined Nomenclature of the European Union [2] are hereby amended as follows:

On page 379

9403 Other furniture and parts thereof

The following text shall be added after the existing text:

'This heading does not include "information displays" such as "street boards" and "roll-ups".

They are to be classified in other headings of the Nomenclature under which they are more specifically included (for example, street boards with writing or drawing surfaces corresponding to products of heading 9610) or according to their constituent material:

(a) under a heading specifically covering these articles (for example, plates of base metal corresponding to products of heading 8310 are classified under this heading), or

(b) under a heading covering various articles of this material (for example, heading 3926 or heading 7616).

Example of a street board to be classified in heading 9610:

Street board with a blackboard surface.

Example of a street board to be classified in heading 8310:



Street board made solely of base metal.

[1] Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (OJ L 256, 7.9.1987, p. 1).
[2] OJ C 76, 4.3.2015, p. 1.

Examples of “information displays” which are to be classified according to their constituent material, under a heading covering various articles of this material:

	
A base of hard plastics, a top of an aluminium frame with a plastic sheet in the middle covered by transparent PVC foils from both sides.	A base and a frame of aluminium with rubber attachments and transparent PVC foils covering a sheet of paper.
Heading 7616 (the essential character is provided by the aluminium frame).	Heading 7616 (the essential character is provided by the aluminium frame).
	
A central plastic plate attached to five plastic rods (bars) of almost equal length, all of which can be tilted in different directions. Four of them have a plastic hook at the end and a plastic cap is mounted on the fifth rod.	
Heading 3926 (the article is made solely of plastics).’	

New national side of euro coins intended for circulation

(2018/C 305/06)

National side of the new commemorative 2-euro coin intended for circulation and issued by Luxembourg

Euro coins intended for circulation have legal tender status throughout the euro area. For the purpose of informing the public and all parties who handle the coins, the Commission publishes a description of the designs of all new coins [1]. In accordance with the Council conclusions of 10 February 2009 [2], euro-area Member States and countries that have concluded a monetary agreement with the European Union providing for the issuing of euro coins are allowed to issue commemorative euro coins intended for circulation, provided that certain conditions are met, particularly that only the 2-euro denomination is used. These coins have the same technical characteristics as other 2-euro coins, but their national face features a commemorative design that is highly symbolic in national or European terms.

Issuing country: Luxembourg

Subject of commemoration: The 175th anniversary of the death of the Grand Duke Guillaume Ist

Description of the design: The design shows on the right hand the effigy of His Royal Highness, the Grand Duke Henri, looking to the left and on the left hand the effigy of HRH the Grand Duke Guillaume Ist. Between both effigies are depicted vertically the year-dates '1772-1843' as well as the name 'Guillaume Ier'. At the bottom appears the text 'LUXEMBOURG' and the year-date '2018'.

The coin's outer ring depicts the 12 stars of the European flag.

Estimated number of coins to be issued: 500 000

Date of issue: September 2018

---

[1] See OJ C 373, 28.12.2001, p. 1 for the national faces of all the coins issued in 2002.

[2] See the conclusions of the Economic and Financial Affairs Council of 10 February 2009 and the Commission Recommendation of 19 December 2008 on common guidelines for the national sides and the issuance of euro coins intended for circulation (OJ L 9, 14.1.2009, p. 52).

EUROPEAN DATA PROTECTION SUPERVISOR

Summary of the opinion on the proposal for a recast of the Public Sector Information (PSI) re-use Directive

(The full text of this Opinion can be found in English, French and German on the EDPS website www.edps.europa.eu)

(2018/C 305/07)

The Public Sector Information (PSI) Directive aims to facilitate the re-use of public sector information throughout the European Union by harmonising the basic conditions that make PSI available to re-users, to enhance the development of Community products and services based on PSI and to avoid distortions in competition.

The new provisions include the extension of the scope of the Directive to documents held by public undertakings active in the areas on procurement such as entities operating in the water, energy, transport and postal services sectors. Moreover, it applies to documents held by public undertakings acting as public services operators, as long as such documents are produced as part of the services in the general interest. In addition, the Proposal's scope will also be extended to specific research data such as results of scientific fact-finding processes.

The Opinion focuses on specific recommendations in order to better clarify the relation and coherence of the PSI Directive with the GDPR exceptions and on the reference to applicable data protection law. Additionally it provides for further recommendations on anonymisation and its relation to costs and data protection, also focusing on a data protection impact assessment, while taking into account an 'acceptable re-use policy'.

The EDPS with this Opinion on PSI re-use builds on the work already done on the 'Good Big Data' (the 'EU values-based data sharing'), and notably on EDPS opinions and formal comments previously issued, consistently with our practice on supervision cases. Moreover, we point out to the issues that need harmonization at EU level to allow the recast of the PSI Directive to rip the expected benefits.

In the context of Article 1(2)(g) of the Proposal, the EDPS recommends to better clarify the relationship and coherence of the PSI with the GDPR by putting forward a drafting suggestion.

Moreover, the EDPS suggests to re-introduce the specific provision currently contained in Article 1(4) of the Directive 2013/37/EU in the main provisions of the Directive and to clealry state in the Proposal that the definition of 'personal data' according to Article 4(1) of the GDPR applies. The EDPS also recommends to add the reference to the Supervisory Authority set up by Article 51 of the GDPR under Article 4(4) of the Proposal.

The EDPS also recommends to support the use of anonymisation by making a reference to 'anonymous information' in the legal text and extending the scope of the entities entitled to include anonmysation costs within the costs that can be charged to reusers.

As a last recommendation, the EDPS suggests to provide for data protection impact assessments, for specific sectors dealing with sensitive data, such as the health sector, on which the licensor should base its decision and consequently take into account the conditions for re-use.

1. INTRODUCTION AND BACKGROUND

1. On 25 April 2018, the Commission adopted a Proposal for a Directive amending Directive 2013/37/EU (following a review of Directive 2003/98/EC) on the re-use of public sector information (PSI) (the 'Proposal'). The Proposal is part of the '2018 Data Package', which also includes other important documents: (i) a Commission Communication entitled 'Towards a common European data space' (the 'Communication'); (ii) Guidance on sharing private sector data, in the form of a Staff Working Document ('Guidance'); and (iii) an evaluation of the PSI Directive.

2. The objective of the Proposal is to update and amend the existing text of Directive 2013/37/EU and Directive 2003/98/EC on re-use of public sector information (the PSI Directive).

3. The review of the Directive is one of the three 'measures' proposed by the Commission towards a common data space in the EU (see the 'umbrella' Communication from the Commission COM (2018) 232, hence 'the Communication'), together with the Guidance on sharing private sector data […] and the update of the Recommendation on access to and preservation of scientific information […].

4. In proposing to amend the PSI Directive, the European Commission aims to facilitate the re-use of public sector information such as legal, traffic, meteorological, economic and financial data throughout the European Union by harmonising the basic conditions that make PSI available to re-users, to enhance the development of Community products and services based on PSI and to avoid distortions in competition.

5. In particular, the Proposal's overall objective is to be in line with the Digital Single Market Strategy's objectives. The Proposal aims to enhance the effect of the Directive by strengthening specific provisions and modifying them accordingly in order to increase the amount of public sector data available for re-use. Specifically, the initiative also aims to strengthen Small and Medium Enterprises' position in the data market by granting fairer competition and an easier access to markets, together with the enhancement of cross-border innovation.

6. Relevant new provisions to the Directive include the extension of its scope to documents held by public undertakings active in the areas on procurement by entities operating in the water, energy, transport and postal services sectors. Moreover, it applies to documents held by public undertakings acting as public services operators, as long as such documents are produced as part of the services in the general interest. The proposal's scope will also be extended to specific research data such as results of scientific fact-finding processes (i.e. experiments and surveys). The Proposal in practice *'(…) lays down a horizontal framework providing minimum harmonisation of reuse conditions across domains and sectors.'* ([1])

7. The EDPS positively notes that according to the European Commission the recast of the PSI Directive aims to foster the reuse of public sector information, as pointed out in the Communication, by *'reducing market entry barriers, in particular for small and medium-sized enterprises; minimising the risk of excessive first-mover advantage, which benefits large companies and thereby limits the number of users of the data in question; increasing business opportunities by encouraging the publication of dynamic data and the uptake of application programming interfaces (APIs).'* ([2])

8. The PSI directive is part of the EU vision on the fostering of 'Good Big Data'. Public sector information is a key source of 'the raw material' of the Big Data of the Digital Single Market. The smart use of data, including its processing via Artificial Intelligence, can have a transformative effect on all sectors of the economy.

9. Already in September 2016, the EDPS, with the *Opinion on coherent enforcement of fundamental rights in the age of big data* ([3]), has put forward a strategy for shaping an EU cyberspace based on EU values, pointing out to issues such as concentration of market and informational power; and a weak market for Privacy Enhancing Technologies ('PETs') as measures for minimising personal data processing without losing the functionality of a product or a service (as inspired by the principle of privacy by design ([4]) and by default).

10. Moreover, the EDPS would like to recall the data protection-relevance of the 'key principles' that, according to the European Commission, should be respected in the context of data re-use, namely (i) minimised data lock-in and ensure undistorted competition; (ii) transparency and societal participation on the purpose of the reuse vis-à-vis the citizens/ data subjects as well as transparency and clear purpose definition between the licensor and the licensees; (iii) data protection impact assessment and appropriate data protection safeguards for reuse (according to a 'do no harm'- under the data protection viewpoint- principle).

11. While the EDPS has been informally consulted by the European Commission, it has not been formally consulted as required by Article 28(2) of Regulation (EC) No 45/2001. The Opinion is therefore based on Article 41(2) of the same Regulation. The EDPS recommends that a reference to this Opinion be included in the preamble of the adopted instrument.

([1]) Explanatory memorandum to the Proposal for a Directive of the European Parliament and the Council on the re-use of public sector information (recast), p. 3.
([2]) Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions 'Towards a common European data space', p. 5
([3]) https://edps.europa.eu/sites/edp/files/publication/16-09-23_bigdata_opinion_en.pdf, on re-use, p. 9.
([4]) European Data Protection Supervisor Opinion 05/2018-Preliminary Opinion on Privacy by Design

7. **CONCLUSION**

Therefore the EDPS recommends:

— to modify Article 1(2)(g) of the Proposal and to provide for specific wording on the difference between 'documents' and 'parts of documents' to which the PSI Directive would not be applicable on data protection grounds.

— to add a reference to the Supervisory Autority set up by Article 51 of the GDPR under Article 4(4) of the Proposal, in order to further enhance the link between the re-use of public sector information and the protection of personal data.

— to re-introduce the specific provision on applicable data protection law currently contained in Article 1(4) of Directive 2013/37/EU in the substantive part of the Proposal (including the necessary update of references to the legal instruments currently in force).

— to further point out to the use of anonymisation in the context of the reuse of public sector information by including a reference to 'anonymous information' in the legal text and extending the scope of the entities entitled to include anonmysation costs within the costs that can be charged to reusers.

— to clearly state in the Proposal that the definition of 'personal data' according to Article 4(1) of the GDPR applies.

— to provide for data protection impact assessments, for specific sectors dealing with sensitive data, such as the health sector, on which the licensor should base its decision and consequently take into account the conditions for re-use.

— As a last comment, in putting forward these recommendations, the EDPS stresses the data protection-relevance of the following 'key principles', that according to the Commission should be respected in the context of data re-use, namely:

(i) Minimised data lock-in and ensure undistorted competition;

(ii) Transparency and societal participation on the purpose of the reuse *vis-à-vis* the citizens/data subjects as well as transparency and clear purpose definition between the licensor and the licensees;

(iii) Data protection impact assessment and appropriate data protection safeguards for reuse (according to a 'do no harm' -under the data protection viewpoint- principle).

Brussels, 10 July 2018.

Giovanni BUTTARELLI

European Data Protection Supervisor

NOTICES FROM MEMBER STATES

Commission information notice pursuant to Article 16 (4) of Regulation (EC) 1008/2008 of the European Parliament and of the Council on common rules for the operation of air services in the Community

Imposition of public service obligations in respect of scheduled air services

(Text with EEA relevance)

(2018/C 305/08)

Member State	Portugal
Route concerned	Bragança - Vila Real – Viseu – Cascais – Portimão – Cascais – Viseu – Vila Real - Bragança
Date of entry into force of the public service obligations	As from 23 December 2018
Address where the text and any relevant information and/or documentation relating to the public service obligations can be obtained	All documents are available at: http://www.saphety.com For more information, please contact: Ministry of Planning and Infrastructure Office of the Secretary of State for Infrastructure Av. Barbosa do Bocage n.º 5 – 2.º andar 1049-039 Lisboa PORTUGAL Email: gab.infraestruturas@mpi.gov.pt

Commission information notice pursuant to Article 16(4) of Regulation (EC) No 1008/2008 of the European Parliament and of the Council on common rules for the operation of air services in the Community

Modification of public service obligations in respect of scheduled air services

(Text with EEA relevance)

(2018/C 305/09)

Member State	United Kingdom
Route concerned	Oban – Coll Oban – Colonsay Oban – Tiree Coll – Tiree
Original date of entry into force of the public service obligations	2 March 2007
Date of entry into force of modifications	16 May 2019
Address where the text and any relevant information and/or documentation relating to the public service obligation can be obtained	All documents will be available from: http://www.publiccontractsscotland.gov.uk For further information please contact: Argyll and Bute Council Council Offices Kilmory Lochgiphead Argyll and Bute Council PA31 8RT Scotland UNITED KINGDOM Tel. +44 1546604239 Contact: Christine Todd Email: Christine.Todd@argyll-bute.gov.uk

Commission information notice pursuant to Article 17(5) of Regulation (EC) No 1008/2008 of the European Parliament and of the Council on common rules for the operation of air services in the Community

Invitation to tender in respect of the operation of scheduled air services in accordance with public service obligations

(Text with EEA relevance)

(2018/C 305/10)

Member State	United Kingdom
Route concerned	Oban – Coll Oban – Colonsay Oban – Tiree Coll – Tiree
Period of validity of the contract	16 May 2019-15 May 2022
Deadline for submission of applications and tenders	19 November 2018
Address from which the text of the invitation to tender and any relevant information and/or documentation relating to the public tender and the public service obligation can be obtained	All documents will be available from: http://www.publiccontractsscotland.gov.uk For further information please contact: Argyll and Bute Council Council Offices Kilmory Lochgiphead Argyll and Bute Council PA31 8RT Scotland UNITED KINGDOM Tel. +44 1546604239 Contact: Christine Todd Email: Christine.Todd@argyll-bute.gov.uk

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

STANDING COMMITTEE OF THE EFTA STATES

Dangerous substances — List of authorisation decisions taken by the EEA EFTA States in accordance with Article 64(8) of Regulation (EC) No 1907/2006 (REACH) in the second half of 2017

(2018/C 305/11)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 25/2008 of 14 March 2008, the EEA Joint Committee is invited to note the following lists concerning authorisation decisions adopted on the basis of Article 64(8) of Regulation (EC) No 1907/2006 (REACH) for the period 1 July – 31 December 2017, at their meeting on 27 April 2018.

ANNEX

List of authorisation decisions

The following authorisation decisions in accordance with Article 64(8) of Regulation (EC) No 1907/2006 (REACH) have been taken in the EEA EFTA States during the period 1 July – 31 December 2017:

Substance name	Commission decision under Article 64(8) of Regulation (EC) No 1907/2006	Country	Date of decision
Ammonium dichromate	C(2017) 3237	Iceland	7.7.2017
Sodium dichromate	C(2017) 3453	Iceland	7.7.2017
Sodium dichromate	C(2017) 3764	Iceland	7.7.2017
Sodium dichromate	C(2017) 3765	Iceland	7.7.2017
Sodium dichromate	C(2017) 3801	Iceland	7.7.2017
Sodium dichromate	C(2017) 3806	Iceland	7.7.2017
Sodium dichromate	C(2017) 3816	Iceland	7.7.2017
1,2-dichloroethane	C(2017) 3821	Iceland	7.7.2017
Potassium dichromate	C(2017) 3910	Iceland	7.7.2017
Chromium trioxide and dichromium tris(chromate)	C(2017) 5001	Iceland	5.10.2017
Chromium trioxide and dichromium tris(chromate)	C(2017) 5001	Liechtenstein	4.9.2017
Chromium trioxide and dichromium tris(chromate)	C(2017) 5001	Norway	18.8.2017
Bis(2-methoxyethyl)ether (diglyme)	C(2017) 5025	Iceland	5.10.2017
Bis(2-methoxyethyl)ether (diglyme)	C(2017) 5025	Liechtenstein	4.9.2017
Bis(2-methoxyethyl)ether (diglyme)	C(2017) 5025	Norway	18.8.2017
Lead chromate	C(2017) 5012	Iceland	5.10.2017
Lead chromate	C(2017) 5012	Liechtenstein	4.9.2017
Lead chromate	C(2017) 5012	Norway	18.8.2017
Chromium trioxide	C(2017) 5880	Iceland	5.10.2017
Chromium trioxide	C(2017) 5880	Liechtenstein	20.9.2017
Chromium trioxide	C(2017) 5880	Norway	25.9.2017
Chromium trioxide	C(2017) 6727	Iceland	9.11.2017
Chromium trioxide	C(2017) 6727	Liechtenstein	25.10.2017
Chromium trioxide	C(2017) 6727	Norway	8.11.2017

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2017

(2018/C 305/12)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July-31 December 2017, at their meeting on 23 March 2018:

Annex I List of new marketing authorisations

Annex II List of renewed marketing authorisations

Annex III List of extended marketing authorisations

Annex IV List of withdrawn marketing authorisations

Annex V List of suspended marketing authorisations

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July-31 December 2017:

EU Number	Product	Country	Date of authorisation
EU/1/02/226	InductOs	Iceland	18.8.2017
EU/1/15/999	Zykadia (Switch to non-conditional)	Liechtenstein	31.8.2017
EU/1/16/1138	Venclyxto	Liechtenstein	31.12.2017
EU/1/16/1155	Kyntheum	Iceland	16.8.2017
EU/1/16/1155	Kyntheum	Liechtenstein	31.8.2017
EU/1/16/1155	Kyntheum	Norway	14.8.2017
EU/1/17/1179	Veltassa	Iceland	11.8.2017
EU/1/17/1179	Veltassa	Liechtenstein	31.8.2017
EU/1/17/1179	Veltassa	Norway	9.8.2017
EU/1/17/1181	Spherox	Iceland	24.7.2017
EU/1/17/1181	Spherox	Liechtenstein	31.8.2017
EU/1/17/1181	Spherox	Norway	13.9.2017
EU/1/17/1184	Riximyo	Iceland	11.7.2017
EU/1/17/1185	Rixathon	Iceland	11.7.2017
EU/1/17/1191	Dinutuximab beta Apeiron	Liechtenstein	31.8.2017
EU/1/17/1194	Febuxostat Mylan	Iceland	11.7.2017
EU/1/17/1195	Erelzi	Iceland	14.7.2017
EU/1/17/1195	Erelzi	Norway	7.7.2017
EU/1/17/1196	Kevzara	Iceland	14.7.2017

EU Number	Product	Country	Date of authorisation
EU/1/17/1196	Kevzara	Norway	5.7.2017
EU/1/17/1197	Oxervate	Iceland	24.7.2017
EU/1/17/1197	OXERVATE	Liechtenstein	31.8.2017
EU/1/17/1197	OXERVATE	Norway	17.7.2017
EU/1/17/1199	Cuprior	Iceland	13.9.2017
EU/1/17/1199	Cuprior	Liechtenstein	31.10.2017
EU/1/17/1199	Cuprior	Norway	13.9.2017
EU/1/17/1200	Besponsa	Iceland	24.7.2017
EU/1/17/1200	Besponsa	Liechtenstein	31.8.2017
EU/1/17/1200	Besponsa	Norway	13.7.2017
EU/1/17/1201	Skilarence	Iceland	14.7.2017
EU/1/17/1201	Skilarence	Norway	7.7.2017
EU/1/17/1202	Ucedane	Iceland	12.7.2017
EU/1/17/1202	Ucedane	Norway	5.7.2017
EU/1/17/1203	Insulin lispro Sanofi	Iceland	11.8.2017
EU/1/17/1203	Insulin Lispro Sanofi	Liechtenstein	31.8.2017
EU/1/17/1203	Insulin lispro Sanofi	Norway	18.8.2017
EU/1/17/1205	Blitzima	Iceland	9.8.2017
EU/1/17/1205	Blitzima	Liechtenstein	31.8.2017
EU/1/17/1205	Blitzima	Norway	1.8.2017
EU/1/17/1206	Tuxella	Iceland	9.8.2017
EU/1/17/1206	Tuxella	Liechtenstein	31.8.2017

EU Number	Product	Country	Date of authorisation
EU/1/17/1206	Tuxella	Norway	1.8.2017
EU/1/17/1207	Ritemvia	Liechtenstein	31.8.2017
EU/1/17/1207	Ritemvia	Iceland	10.8.2017
EU/1/17/1207	Ritemvia	Norway	1.8.2017
EU/1/17/1208	Trimbow	Iceland	11.8.2017
EU/1/17/1208	Trimbow	Liechtenstein	31.8.2017
EU/1/17/1208	Trimbow	Norway	9.8.2017
EU/1/17/1209	Reagila	Iceland	9.8.2017
EU/1/17/1209	Reagila	Liechtenstein	31.8.2017
EU/1/17/1209	Reaglia	Norway	9.8.2017
EU/1/17/1210	Efavirenz/Emtricitabin/Tenofovirdisproksil Zentiva	Norway	8.8.2017
EU/1/17/1210	Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva	Iceland	10.8.2017
EU/1/17/1210	Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva	Liechtenstein	31.8.2017
EU/1/17/1211	Entecavir Accord	Iceland	5.10.2017
EU/1/17/1211	Entecavir Accord	Liechtenstein	31.10.2017
EU/1/17/1211	Entecavir Accord	Norway	20.10.2017
EU/1/17/1212	Mavenclad	Iceland	13.9.2017
EU/1/17/1212	MAVENCLAD	Norway	30.8.2017
EU/1/17/1212	MAVENCLAD	Liechtenstein	31.8.2017
EU/1/17/1213	Maviret	Iceland	17.8.2017
EU/1/17/1213	Maviret	Liechtenstein	31.8.2017
EU/1/17/1213	Maviret	Norway	7.8.2017

EU Number	Product	Country	Date of authorisation
EU/1/17/1214	Bavencio	Iceland	4.10.2017
EU/1/17/1214	Bavencio	Liechtenstein	31.10.2017
EU/1/17/1214	Bavencio	Norway	25.9.2017
EU/1/17/1215	Fotivda	Iceland	13.9.2017
EU/1/17/1215	Fotivda	Liechtenstein	31.8.2017
EU/1/17/1215	Fotivda	Norway	31.8.2017
EU/1/17/1216	Imraldi	Iceland	12.9.2017
EU/1/17/1216	Imraldi	Liechtenstein	31.8.2017
EU/1/17/1216	Imraldi	Norway	11.9.2017
EU/1/17/1217	Nitisinone MendeliKABS	Iceland	19.9.2017
EU/1/17/1217	Nitisinone MendeliKABS	Liechtenstein	31.8.2017
EU/1/17/1217	Nitisinone MendeliKABS	Norway	1.9.2017
EU/1/17/1218	Rydapt	Iceland	4.10.2017
EU/1/17/1218	Rydapt	Liechtenstein	31.10.2017
EU/1/17/1218	Rydapt	Norway	25.9.2017
EU/1/17/1220	Tecentriq	Liechtenstein	31.10.2017
EU/1/17/1220	Tecentriq	Norway	27.9.2017
EU/1/17/1220	Tecentriq	Iceland	5.10.2017
EU/1/17/1221	Kisqali	Iceland	12.9.2017
EU/1/17/1221	Kisqali	Norway	30.8.2017
EU/1/17/1221	Kisqali	Liechtenstein	31.8.2017
EU/1/17/1222	Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan	Iceland	8.11.2017

EU Number	Product	Country	Date of authorisation
EU/1/17/1222	Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan	Liechtenstein	31.10.2017
EU/1/17/1222	Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan	Norway	27.9.2017
EU/1/17/1223	Vosevi	Iceland	16.8.2017
EU/1/17/1223	Vosevi	Liechtenstein	31.8.2017
EU/1/17/1223	Vosevi	Norway	8.8.2017
EU/1/17/1224	Xermelo	Iceland	4.10.2017
EU/1/17/1224	Xermelo	Liechtenstein	31.10.2017
EU/1/17/1224	Xermelo	Norway	3.10.2017
EU/1/17/1225	Symtuza	Iceland	5.10.2017
EU/1/17/1225	Symtuza	Liechtenstein	31.10.2017
EU/1/17/1225	Symtuza	Norway	11.10.2017
EU/1/17/1226	Lutathera	Iceland	10.10.2017
EU/1/17/1226	Lutathera	Liechtenstein	31.10.2017
EU/1/17/1226	Lutathera	Norway	3.10.2017
EU/1/17/1227	Entecavir Mylan	Iceland	4.10.2017
EU/1/17/1227	Entecavir Mylan	Liechtenstein	31.10.2017
EU/1/17/1227	Entecavir Mylan	Norway	27.9.2017
EU/1/17/1228	Tookad	Iceland	29.11.2017
EU/1/17/1228	TOOKAD	Liechtenstein	31.12.2017
EU/1/17/1228	TOOKAD	Norway	22.11.2017
EU/1/17/1229	Dupixent	Iceland	10.10.2017
EU/1/17/1229	Dupixent	Liechtenstein	31.10.2017

EU Number	Product	Country	Date of authorisation
EU/1/17/1229	Dupixent	Norway	10.10.2017
EU/1/17/1230	Lacosamide Accord	Iceland	5.10.2017
EU/1/17/1230	Lacosamide Accord	Liechtenstein	31.10.2017
EU/1/17/1230	Lacosamide Accord	Norway	27.9.2017
EU/1/17/1232	Miglustat Gen.Orph	Iceland	30.11.2017
EU/1/17/1232	Miglustat Gen.Orph	Liechtenstein	31.12.2017
EU/1/17/1232	Miglustat Gen.Orph	Norway	27.11.2017
EU/1/17/1233	Zubsolv	Iceland	29.11.2017
EU/1/17/1233	Zubsolv	Liechtenstein	31.12.2017
EU/1/17/1233	Zubsolv	Norway	22.11.2017
EU/1/17/1234	Tremfya	Iceland	4.12.2017
EU/1/17/1235	Zejula	Iceland	4.12.2017
EU/1/17/1235	Zejula	Liechtenstein	31.12.2017
EU/1/17/1235	Zejula	Norway	27.11.2017
EU/1/17/1236	Trelegy Ellipta	Iceland	30.11.2017
EU/1/17/1236	Trelegy Ellipta	Liechtenstein	31.12.2017
EU/1/17/1236	Trelegy Ellipta	Norway	22.11.2017
EU/1/17/1237	Elebrato Ellipta	Iceland	30.11.2017
EU/1/17/1237	Elebrato Ellipta	Liechtenstein	31.12.2017
EU/1/17/1237	Elebrato Ellipta	Norway	27.11.2017
EU/1/17/1238	Nyxoid	Iceland	29.11.2017
EU/1/17/1238	Nyxoid	Liechtenstein	31.12.2017

EU Number	Product	Country	Date of authorisation
EU/1/17/1238	Nyxoid	Norway	27.11.2017
EU/1/17/1239	VeraSeal	Iceland	30.11.2017
EU/1/17/1239	VeraSeal	Liechtenstein	31.12.2017
EU/1/17/1239	VeraSeal	Norway	1.12.2017
EU/1/17/1240	Cyltezo	Iceland	29.11.2017
EU/1/17/1240	Cyltezo	Liechtenstein	31.12.2017
EU/1/17/1240	Cyltezo	Norway	1.12.2017
EU/1/17/1241	Ontruzant	Iceland	30.11.2017
EU/1/17/1241	Ontruzant	Liechtenstein	31.12.2017
EU/1/17/1241	Ontruzant	Norway	27.11.2017
EU/1/17/1242	Ritonavir Mylan	Iceland	29.11.2017
EU/1/17/1242	Ritonavir Mylan	Liechtenstein	31.12.2017
EU/1/17/1242	Ritonavir Mylan	Norway	22.11.2017
EU/1/17/1243	Imatinib Teva B.V.	Iceland	30.11.2017
EU/1/17/1243	Imatinib Teva B.V.	Liechtenstein	31.12.2017
EU/1/17/1243	Imatinib Teva B.V.	Norway	22.11.2017
EU/1/17/1244	Tacforius	Liechtenstein	31.12.2017
EU/2/16/197	CLYNAV	Iceland	13.7.2017
EU/2/16/197	CLYNAV	Liechtenstein	31.8.2017
EU/2/16/197	CLYNAV	Norway	18.7.2017
EU/2/17/211	Prevomax	Iceland	13.7.2017
EU/2/17/211	Prevomax	Norway	6.7.2017

EU Number	Product	Country	Date of authorisation
EU/2/17/212	Exzolt	Iceland	30.8.2017
EU/2/17/212	Exzolt	Liechtenstein	31.10.2017
EU/2/17/212	Exzolt	Norway	15.9.2017
EU/2/17/213	Innovax-ND-IBD	Iceland	11.9.2017
EU/2/17/213	Innovax-ND-IBD	Norway	18.9.2017
EU/2/17/214	VEPURED	Iceland	12.9.2017
EU/2/17/214	VEPURED	Norway	15.9.2017
EU/2/17/215	Suvaxyn PRRS MLV	Iceland	11.9.2017
EU/2/17/215	Suvaxyn PRRS MLV	Liechtenstein	31.10.2017
EU/2/17/215	Suvaxyn PRRS MLV	Norway	18.9.2017
EU/2/17/217	Nobivac LeuFel	Iceland	9.11.2017
EU/2/17/217	Nobivac LeuFel	Liechtenstein	31.12.2017
EU/2/17/217	Nobivac LeuFel	Norway	14.11.2017
EU/2/17/218	Bovilis Blue-8	Iceland	1.12.2017
EU/2/17/218	Bovilis Blue-8	Liechtenstein	31.12.2017
EU/2/17/218	Bovilis Blue-8	Norway	19.12.2017

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July-31 December 2017:

EU Number	Product	Country	Date of authorisation
EU/1/07/401	alli	Iceland	14.7.2017
EU/1/07/401	alli	Liechtenstein	31.8.2017
EU/1/07/401	alli	Norway	5.7.2017
EU/1/07/402	Increlex	Iceland	12.7.2017
EU/1/07/402	INCRELEX	Norway	5.7.2017
EU/1/07/403	Atriance	Iceland	11.7.2017
EU/1/07/416	Ecalta	Iceland	13.9.2017
EU/1/07/416	Ecalta	Liechtenstein	31.10.2017
EU/1/07/416	Ecalta	Norway	22.9.2017
EU/1/07/421	Glubrava	Iceland	30.11.2017
EU/1/07/421	Glubrava	Liechtenstein	31.12.2017
EU/1/07/421	Glubrava	Norway	22.11.2017
EU/1/07/424	Torisel	Iceland	24.7.2017
EU/1/07/424	Torisel	Liechtenstein	31.8.2017
EU/1/07/424	Torisel	Norway	1.8.2017
EU/1/08/446	Privigen	Iceland	4.12.2017
EU/1/08/446	Privigen	Liechtenstein	31.12.2017
EU/1/08/446	Privigen	Norway	5.12.2017
EU/1/08/453	Prepandrix	Iceland	4.12.2017

EU Number	Product	Country	Date of authorisation
EU/1/08/453	Prepandrix	Liechtenstein	31.12.2017
EU/1/08/453	Prepandrix	Norway	5.12.2017
EU/1/12/784	Cuprymina	Iceland	11.8.2017
EU/1/12/784	Cuprymina	Liechtenstein	31.8.2017
EU/1/12/784	Cuprymina	Norway	9.8.2017
EU/1/12/787	Revestive	Iceland	13.7.2017
EU/1/12/787	Revestive	Norway	5.7.2017
EU/1/12/788	Seebri Breezhaler	Iceland	11.8.2017
EU/1/12/788	Seebri Breezhaler	Liechtenstein	31.8.2017
EU/1/12/788	Seebri Breezhaler	Norway	9.8.2017
EU/1/12/789	Enurev Breezhaler	Iceland	24.7.2017
EU/1/12/789	Enurev Breezhaler	Liechtenstein	31.8.2017
EU/1/12/789	Enurev Breezhaler	Norway	9.8.2017
EU/1/12/790	Tovanor Breezhaler	Iceland	14.8.2017
EU/1/12/790	Tovanor Breezhaler	Liechtenstein	31.8.2017
EU/1/12/790	Tovanor Breezhaler	Norway	9.8.2017
EU/1/12/794	Adcetris	Iceland	4.12.2017
EU/1/12/794	ADCETRIS	Liechtenstein	31.12.2017
EU/1/12/794	ADCETRIS	Norway	27.11.2017
EU/1/12/795	Forxiga	Iceland	13.9.2017
EU/1/12/795	Forxiga	Liechtenstein	31.10.2017
EU/1/12/795	Forxiga	Norway	27.9.2017

EU Number	Product	Country	Date of authorisation
EU/1/12/796	Picato	Iceland	24.7.2017
EU/1/12/796	Picato	Liechtenstein	31.8.2017
EU/1/12/796	Picato	Norway	8.8.2017
EU/1/12/797	Eylea	Iceland	10.8.2017
EU/1/12/797	Eylea	Liechtenstein	31.8.2017
EU/1/12/797	Eylea	Norway	18.8.2017
EU/1/12/798	Ibandronic acid Accord	Iceland	6.10.2017
EU/1/12/798	Ibandronic acid Accord	Liechtenstein	31.10.2017
EU/1/12/798	Ibandronic acid Accord	Norway	27.9.2017
EU/1/12/799	Memantine Merz	Iceland	24.7.2017
EU/1/12/799	Memantine Merz	Liechtenstein	31.8.2017
EU/1/12/799	Memantine Merz	Norway	9.8.2017
EU/1/12/800	Zoledronic Acid Hospira	Iceland	11.9.2017
EU/1/12/800	Zoledronic acid Hospira	Liechtenstein	31.8.2017
EU/1/12/800	Zoledronsyre Hospira	Norway	4.9.2017
EU/1/12/801	Constella	Iceland	14.9.2017
EU/1/12/801	Constella	Liechtenstein	31.10.2017
EU/1/12/801	Constella	Norway	22.9.2017
EU/1/12/802	Capecitabine medac	Iceland	12.7.2017
EU/1/12/803	NexoBrid	Iceland	30.11.2017
EU/1/12/803	NexoBrid	Liechtenstein	31.12.2017
EU/1/12/803	NexoBrid	Norway	11.12.2017

EU Number	Product	Country	Date of authorisation
EU/1/12/805	AMYViD	Iceland	9.10.2017
EU/1/12/805	Amyvid	Liechtenstein	31.10.2017
EU/1/12/805	Amyvid	Norway	3.10.2017
EU/1/12/806	Ryzodeg	Iceland	4.10.2017
EU/1/12/806	Ryzodeg	Liechtenstein	31.10.2017
EU/1/12/806	Ryzodeg	Norway	10.10.2017
EU/1/12/807	Tresiba	Iceland	9.10.2017
EU/1/12/807	Tresiba	Liechtenstein	31.10.2017
EU/1/12/807	Tresiba	Norway	10.10.2017
EU/1/12/808	Imatinib Teva	Iceland	9.10.2017
EU/1/12/808	Imatinib Teva	Liechtenstein	31.10.2017
EU/1/12/808	Imatinib Teva	Norway	27.9.2017
EU/1/12/809	Betmiga	Iceland	6.10.2017
EU/1/12/809	Betmiga	Liechtenstein	31.10.2017
EU/1/12/809	Betmiga	Norway	3.10.2017
EU/1/12/811	Lyxumia	Iceland	6.10.2017
EU/1/12/811	Lyxumia	Liechtenstein	31.10.2017
EU/1/12/811	Lyxumia	Norway	9.10.2017
EU/1/12/812	Bexsero	Iceland	9.10.2017
EU/1/12/812	Bexsero	Liechtenstein	31.10.2017
EU/1/12/812	Bexsero	Norway	3.10.2017
EU/1/12/814	Zaltrap	Iceland	9.10.2017

EU Number	Product	Country	Date of authorisation
EU/1/12/814	ZALTRAP	Liechtenstein	31.10.2017
EU/1/12/814	ZALTRAP	Norway	27.9.2017
EU/1/12/815	Selincro	Iceland	30.11.2017
EU/1/12/815	Selincro	Liechtenstein	31.12.2017
EU/1/12/815	Selincro	Norway	1.12.2017
EU/1/13/813	Perjeta	Iceland	19.12.2017
EU/1/13/813	Perjeta	Liechtenstein	31.12.2017
EU/1/13/817	Actelsar HCT	Liechtenstein	31.12.2017
EU/1/13/819	JETREA	Iceland	15.12.2017
EU/1/13/819	JETREA	Liechtenstein	31.12.2017
EU/1/13/819	JETREA	Norway	19.12.2017
EU/1/13/902	Translarna	Iceland	12.7.2017
EU/1/13/902	Translarna	Norway	5.7.2017
EU/1/14/987	Holoclar	Iceland	19.12.2017
EU/1/16/1094	Ninlaro	Iceland	6.10.2017
EU/1/16/1094	Ninlaro	Liechtenstein	31.10.2017
EU/1/16/1094	Ninlaro	Norway	26.9.2017
EU/1/16/1121	Zalmoxis	Iceland	24.7.2017
EU/1/16/1121	Zalmoxis	Liechtenstein	31.8.2017
EU/1/16/1121	Zalmoxis	Norway	4.8.2017
EU/1/16/1138	Venclyxto	Iceland	6.11.2017
EU/1/16/1138	Venclyxto	Norway	14.11.2017

EU Number	Product	Country	Date of authorisation
EU/1/16/1139	Ocaliva	Iceland	8.12.2017
EU/1/16/1139	OCALIVA	Liechtenstein	31.12.2017
EU/1/16/1139	OCALIVA	Norway	18.12.2017
EU/1/16/1143	Lartruvo	Iceland	6.10.2017
EU/1/16/1143	Lartruvo	Liechtenstein	31.10.2017
EU/1/16/1143	Lartruvo	Norway	27.9.2017
EU/1/16/1169	Alecensa	Iceland	8.12.2017
EU/1/16/1169	Alecensa	Liechtenstein	31.12.2017
EU/1/16/1169	Alecensa	Norway	15.12.2017
EU/1/43/890	Cometriq	Norway	3.8.2017
EU/2/12/142	Cardalis	Iceland	4.7.2017
EU/2/12/144	Contacera	Iceland	5.12.2017
EU/2/12/144	Contacera	Liechtenstein	31.12.2017
EU/2/12/144	Contacera	Norway	15.12.2017
EU/2/12/145	Kexxtone	Liechtenstein	31.12.2017
EU/2/12/145	Kexxtone	Norway	28.12.2017
EU/2/12/147	Pexion	Iceland	5.12.2017
EU/2/12/147	Pexion	Liechtenstein	31.12.2017
EU/2/12/147	Pexion	Norway	6.12.2017

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July-31 December 2017:

EU Number	Product	Country	Date of authorisation
EU/1/01/177/002	SonoVue	Norway	4.9.2017
EU/1/03/256/022	Humira	Iceland	19.12.2017
EU/1/03/256/022	Humira	Norway	10.11.2017
EU/1/04/292/013-015	Mimpara	Iceland	15.9.2017
EU/1/04/292/013-015	Mimpara	Norway	28.8.2017
EU/1/06/356/020-022	Exjade	Norway	28.11.2017
EU/1/06/356/020-022	Exjade	Iceland	1.12.2017
EU/1/07/418/011-013	Celsentri	Norway	3.8.2017
EU/1/07/418/011-013	Celsentri	Iceland	13.7.2017
EU/1/07/422/015	Tasigna	Iceland	4.12.2017
EU/1/07/422/015	Tasigna	Norway	28.11.2017
EU/1/07/436/006	Isentress	Iceland	9.8.2017
EU/1/07/436/006	Isentress	Norway	7.8.2017
EU/1/08/481/004-005	Kuvan	Iceland	10.8.2017
EU/1/08/481/004-005	Kuvan	Norway	13.7.2017
EU/1/09/522/003	ellaOne	Iceland	1.12.2017
EU/1/09/522/003	ellaOne	Norway	10.11.2017
EU/1/09/531/022-033	Instanyl	Iceland	6.11.2017
EU/1/09/539/005-006	Samsca	Iceland	5.10.2017

EU Number	Product	Country	Date of authorisation
EU/1/09/539/005-006	Samsca	Norway	18.9.2017
EU/1/10/618	Prolia	Norway	27.9.2017
EU/1/11/703	Xgeva	Norway	27.9.2017
EU/1/12/753/018-019	Signifor	Iceland	4.10.2017
EU/1/12/753/018-019	Signifor	Norway	18.9.2017
EU/1/12/787/003	Revestive	Norway	5.7.2017
EU/1/12/787/003	Revestive	Iceland	13.7.2017
EU/1/13/846/002-003	Xtandi	Norway	3.10.2017
EU/1/13/846/002-003	Xtandi	Iceland	6.10.2017
EU/1/13/860/003	Nexium Control	Iceland	11.7.2017
EU/1/13/860/003	Nexium Control	Norway	5.7.2017
EU/1/15/1070/002	Oncaspar	Iceland	19.12.2017

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July-31 December 2017:

EU Number	Product	Country	Date of withdrawal
EU/1/00/167	Prevenar	Liechtenstein	31.12.2017
EU/1/00/167	Prevenar	Norway	11.12.2017
EU/1/00/167	Prevenar	Iceland	1.12.2017
EU/1/07/394	Optaflu	Norway	18.10.2017
EU/1/07/398	Optimark	Iceland	10.10.2017
EU/1/09/561	Clopidogrel Teva Pharma	Iceland	11.7.2017
EU/1/11/674	Repso	Liechtenstein	31.8.2017
EU/1/11/674	Repso	Norway	8.8.2017
EU/1/11/674	Repso	Iceland	10.8.2017
EU/1/13/868	EVARREST	Liechtenstein	31.12.2017
EU/1/13/868	EVARREST	Norway	28.11.2017
EU/1/13/868	EVARREST	Iceland	4.12.2017
EU/1/14/976	Zontivity	Liechtenstein	31.8.2017
EU/1/15/996	Ristempa	Liechtenstein	31.10.2017
EU/1/15/996	Ristempa	Norway	9.10.2017
EU/1/15/996	Ristempa	Iceland	9.10.2017
EU/1/16/1113	Enzepi	Iceland	11.8.2017
EU/1/16/1113	Enzepi	Liechtenstein	31.8.2017
EU/1/16/1113	Enzepi	Norway	8.8.2017

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July-31 December 2017:

EU Number	Product	Country	Date of suspension

V

(Announcements)

ADMINISTRATIVE PROCEDURES

EUROPEAN PERSONNEL SELECTION OFFICE (EPSO)

NOTICE OF OPEN COMPETITION

(2018/C 305/13)

The European Personnel Selection Office (EPSO) is organising the following open competition:

EPSO/AST-SC/07/18 — ARMED SECURITY AND PROTECTION OFFICERS (SC 1/SC 2)

The competition notice is published in 24 languages in *Official Journal of the European Union* C 305 A of 30 August 2018.

Further information can be found on the EPSO website: https://epso.europa.eu/

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

EUROPEAN COMMISSION

Prior notification of a concentration

(Case M.9072 — KKR/Altice/SFR Filiale)

Candidate case for simplified procedure

(Text with EEA relevance)

(2018/C 305/14)

1. On 24 August 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— KKR & Co. Inc ('KKR') (USA),

— Altice France S.A. ('Altice') (France), belonging to the Altice group,

— SFR Filiale SAS ('SFR Filiale'), controlled by Altice.

KKR and Altice acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of SFR Filiale.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for KKR: investment firm that provides asset management services and capital markets solutions,

— for Altice: telecoms, content, media, entertainment and advertising services.

— for SFR Filiale: telecommunication towers business of Altice's subsidiary in France, SFR S.A.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 ([2]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9072 — KKR/Altice/SFR Filiale

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').
([2]) OJ C 366, 14.12.2013, p. 5.

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

E-mail: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

ISSN 1977-091X (electronic edition)
ISSN 1725-2423 (paper edition)

Publications Office of the European Union
2985 Luxembourg
LUXEMBOURG

EN